Postoperative dermatologic sequelae of breast cancer in women: a narrative review of the literature

Yana Kost, Ahava Muskat, Beth N. McLellan

Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA

Contributions: (I) Conception and design: BN McLellan; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: Y Kost; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Yana Kost, BA. Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, 3411 Wayne Avenue, Bronx, NY 10467, USA. Email: yana.kost@alumni.einsteinmed.edu.

Background and Objective: Annually, 1.7 million women are diagnosed with breast cancer worldwide. Surgical resection of malignancy plays a central role in breast cancer treatment with recent advancements in surgical technique and cancer treatment allowing for more personalized therapy. With new treatments, novel dermatologic sequelae of breast cancer surgery have been identified, yet no source exists to review postsurgical cutaneous disease in breast cancer patients.

Methods: A PubMed and EMBASE search was conducted in September 2021 using a comprehensive list of terms in three main categories, combined using the AND operator: (I) breast cancer; (II) breast cancer surgery and (III) skin disease.

Key Content and Findings: We identified 12 skin conditions associated with breast cancer surgery, which can be designated into categories: inflammatory, infectious, or lymphedema-associated entities. We provide a comprehensive review of clinical presentation, pathogenesis, and management strategies for cutaneous sequelae routinely seen following breast cancer surgery. Of note, many postsurgical dermatologic sequelae mimic recurrent or metastatic breast malignancy, as well as infectious etiologies, which can be distressing to both the patient and clinician. We also identified several gaps in our knowledge regarding the etiology and treatment of red breast syndrome (RBS) and delayed breast cellulitis (DBC), as well as a need for effective angiosarcoma treatment.

Conclusions: To thoroughly evaluate post-operative skin concerns, a complete history, careful skin exam, and if needed, laboratory workup and skin biopsy should be performed to obtain timely diagnosis and appropriate treatment. Several identified conditions require further research.

Keywords: Breast surgery; dermatologic disease; breast cancer

Received: 24 September 2022; Accepted: 06 June 2023; Published online: 15 June 2023.
doi: 10.21037/abs-22-39

View this article at: https://dx.doi.org/10.21037/abs-22-39
comprehensively detailing the current understanding of presentation, etiology, diagnosis, and management of dermatologic postsurgical and reconstructive sequelae in breast cancer patients. We also identify limits in knowledge of pathogenesis and treatments of such conditions, suggesting areas for needed further research. The condition identified herein are classified as inflammatory, infectious, or lymphedema-associated entities. We present this article in accordance with the Narrative Review reporting checklist (available at https://abs.amegroups.com/article/view/10.21037/abs-22-39/rc).

### Methods

A PubMed and EMBASE search was conducted for articles published between inception of the database and September 2021 using a comprehensive list of terms in three main categories, combined using the AND operator: (I) breast cancer; (II) breast cancer surgery and (III) skin disease (Table S1). Selection criteria was determined prior to review of articles. YK and AM independently conducted the selection. Discrepancies were resolved through author consensus (Table 1).

### Discussion

**Inflammatory**

**Pyoderma gangrenosum (PG)**

PG is a rare neutrophilic ulcerative skin disease commonly associated with skin trauma through pathergy (6–8). Postoperative PG presents at the surgical incision site with erythema or sterile pustules rapidly progressing to skin ulceration with irregular, undermined, violaceous borders, and wound dehiscence with systemic symptoms including fever and leukocytosis in half of patients (6,9) (Figure 1). Breast PG characteristically spares the nipple/areola complex (6) which can differentiate PG from mimickers including infection (8). PG of the breast presents 4 days to 6 weeks postoperatively (8) and latency period is related to the extent of surgery, with larger procedures leading to a shorter disease onset (10). PG pathogenesis is still not well understood. Neutrophil chemotaxis dysregulation due to genetic factors, underlying disease, or cytokine release from trauma caused by surgery may be implicated (6,8,10,11).

Postoperative PG diagnosis is challenging because surgical wound and necrotizing soft tissue infections present similarly (6,12). Misdiagnosis may lead to unnecessary antibiotic therapy or surgical debridement, which exacerbates PG due to pathergy (6). Recently, PG diagnostic criteria were established (13), requiring one major criteria and at least four minor criteria to be satisfied for diagnosis (14) (Table 2). Skin biopsy (or skin obtained during debridement) should be sent for histology as well as bacterial, fungal and mycobacterial cultures to aid in ruling out infection (10). Skin biopsies to evaluate for PG should be obtained from the ulcer edge including ulcerated and intact skin. Other inflammatory, ulcerating dermatologic conditions which have been rarely reported postoperatively on the breast include pemphigus vulgaris (15), ulcerative necrobiosis lipoidica (16), and skin necrosis following methylene blue dye injection for sentinel node biopsy (17). These conditions may be distinguished from PG as

---

**Table 1 Search strategy summary**

<table>
<thead>
<tr>
<th>Items</th>
<th>Specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of search</td>
<td>August 20th–September 6th 2021</td>
</tr>
<tr>
<td>Databases and other sources searched</td>
<td>PubMed and EMBASE</td>
</tr>
<tr>
<td>Search terms used</td>
<td>Comprehensive list of terms in three main categories, combined using the AND operator: (I) breast cancer; (II) breast cancer surgery and (III) skin disease (Table S1)</td>
</tr>
<tr>
<td>Timeframe</td>
<td>Inception of the database through September 2021</td>
</tr>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>All study types included if describing post-surgical skin conditions, risk factors, pathogenesis, and treatments. Studies were excluded if they were not in English</td>
</tr>
<tr>
<td>Selection process</td>
<td>Selection criteria was determined prior to review of articles. YK and AM independently conducted the selection. Discrepancies were resolved through author consensus</td>
</tr>
</tbody>
</table>

---
pemphigus vulgaris frequently presents with mucocutaneous disease and can be definitively diagnosed via biopsy (15), necrobiosis lipoidica often presents first with a yellow atrophic plaque (16), and skin and fat necrosis lacks the characteristic borders of PG (17).

**PG treatment goals include suppressing the inflammatory process, promoting wound healing, treating superimposed infection, and controlling pain (9,18-23)** (*Table 3*). Treatment response to systemic corticosteroids is usually observed within 48 hours with flattening of the ulcer’s raised borders and formation of granulation tissue (8). However, therapy duration is 4.7 months on average due to slow healing (24). PG scars can be significant if diagnosis is delayed (25,26), and surgical revision including skin grafting or flap reconstruction has been successfully performed under steroid coverage (6,27).

**Red breast syndrome (RBS)**

RBS is a non-infectious, self-limited inflammatory entity first described in 2010 in patients undergoing breast reconstruction with an acellular dermal matrix (ADM), a soft connective tissue graft generated by a decellularization process. RBS presents with erythema blanching with pressure overlying the ADM, usually involving the lower pole of the breast, days to weeks after reconstruction (28). RBS incidence may be as high as 7.6% (29) and has been reported rarely with synthetic mesh implantation (28,30).

The exact etiology is uncertain but hypotheses include a delayed type IV allergic reaction to the ADM (28), residual DNA or preservative agents within the ADM, response to vascularization of the ADM, interruption of lymphatic flow due to ADM placement, and hydrolysis of the implanted ADM (30,31). Risk factors include body mass index (BMI) >30, larger breast size, smoking, and axillary dissection (32).

RBS is self-limiting and requires only conservative management but can cause anxiety both for the patient and clinician as it can mimic cellulitis or inflammatory breast cancer (32). However, erythema of RBS directly overlies the ADM unlike the diffuse erythema of cellulitis and there is usually, but not always, absence of infectious manifestations such as local tenderness, warmth, fever, or response to

<table>
<thead>
<tr>
<th>Table 2 Diagnostic criteria of ulcerative pyoderma gangrenosum</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
</tr>
<tr>
<td>Biopsy of ulcer edge demonstrating neutrophilic infiltrate</td>
</tr>
<tr>
<td><strong>Minor criteria (≥4)</strong></td>
</tr>
<tr>
<td>Exclusion of infection</td>
</tr>
<tr>
<td>Pathergy</td>
</tr>
<tr>
<td>History of inflammatory bowel disease or inflammatory arthritis</td>
</tr>
<tr>
<td>History of papule, pustule, or vesicle ulcerating within 4 days</td>
</tr>
<tr>
<td>of appearing</td>
</tr>
<tr>
<td>Peripheral erythema, undermining border, and tenderness at ulceration site</td>
</tr>
<tr>
<td>Multiple ulcerations, at least 1 on an anterior lower leg</td>
</tr>
<tr>
<td>Cribriform or “wrinkled paper” scar(s) at healed ulcer sites</td>
</tr>
<tr>
<td>Decreased ulcer size within 1 month of initiating immunosuppressive medication(s)</td>
</tr>
</tbody>
</table>

Figure 1 Pyoderma gangrenosum. (A) An ulcerated plaque with undermined borders on the breast incision following breast reconstruction in a breast cancer patient; (B) an ulcerated plaque with overlying infection on the breast incision following lumpectomy in a breast cancer patient.
If there is any doubt regarding possible infection, empiric antibiotic treatment is recommended (28). Biopsy can be considered if inflammatory breast carcinoma is a clinical concern. Of note, radiation recall dermatitis (RRD), a skin toxicity triggered by anticancer treatment in patients previously treated with radiation therapy, is a mimicker of RBS (33). RDD commonly presents as an erythematous patch confined to the previously irradiated area and is treated with steroid therapy (33). Careful history-taking can differentiate the two entities. Other dermatologic conditions presenting as an erythematous patch which have been reported postoperatively on the breast include rare inflammatory disorders like morphea (34-36) (Figure 2), eosinophilic cellulitis (37), and erythema annulare centrifugum (38), which are all treated with topical steroids. Additionally, panniculitis following autologous fat graft reconstruction (39) and dermatomyositis precipitated by surgery which may mimic RBS have been reported (40-42).

### Table 3 Pyoderma gangrenosum treatment

<table>
<thead>
<tr>
<th>Anti-inflammatory</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroids</td>
<td></td>
</tr>
<tr>
<td>Indolent or limited disease: topical triamcinolone or tacrolimus applied to the edge of the area twice per week</td>
<td></td>
</tr>
<tr>
<td>Extensive disease: oral prednisone (1 mg/kg/day) or IV methylprednisolone (0.5–1 mg/kg/day) with taper</td>
<td></td>
</tr>
<tr>
<td>Steroid-sparing agents</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine, tacrolimus, cyclophosphamide, colchicine, dapsone, mycophenolate mofetil, methotrexate, thalidomide, IV immune globulin, azathioprine, infliximab, etanercept, adalimumab</td>
<td></td>
</tr>
</tbody>
</table>

Wound healing

- Avoid further trauma/debridement
- Wound care nursing
- Extracellular matrix for support
- Negative pressure dressing
- Hyperbaric oxygen

Pain management

- Prescription-strength opioids

Treating infection

- Application of topical antibacterial agents

**Figure 2** Morphea. A well-demarcated, erythematous patch with a yellow, thickened central area on the left breast of a breast cancer patient.
scaly, erythematous lesions (43,44) (Figure 3). Numerous mechanisms underlying postsurgical dermatitis have been proposed, including transient intraoperative ischemia due to retractor use leading to decreased skin barrier function, increased postoperative skin tension, and disruption of blood vessels or lymphatic channels during surgery, all predisposing the skin to eczematous changes (43,45).

Treatment consists of low-to-mid-potency topical steroids with improvement expected in 2–4 weeks (43). Mupirocin ointment may be added for suspected impetiginization (43). The presence of similar lesions outside the breast area suggests a diagnosis of tinea corporis, treated with topical antifungal medication. In the case of non-resolving lesions despite therapy, biopsy is warranted to rule out cutaneous metastases, local recurrence. If the nipple-areola complex is affected with non-resolving dermatitis, Paget’s disease (PD) and a diagnostic biopsy should be considered (46). PD is characterized by crusted, scaly, or ulcerated lesions and is often associated with an underlying carcinoma (46). Dermatitis may also mimic allergic contact dermatitis to nipple tattoo dye (47), bandages, tape or topical medication (43), or irritant contact dermatitis to various materials like vacuum-based perioperative external tissue expanders or intraoperative iodine use (48,49), which are more likely to present with erythematous vesicles and crusting. Both are treated with removal of the causative agent and topical steroids.

**Burn**

In the last several decades a new complication of breast reconstruction has been described in 38 cases: partial- and full-thickness burns. This clinical entity presents with painful erythema and edema with progression to blistering and pallor, sometimes with necrosis in the operated area with sparing of surrounding skin (50). It has been reported to occur 2 months–5 years after surgery, but occurs more frequently during the first year (50). Most cases have been reported after transverse rectus abdominis flap reconstruction both at the recipient and donor site (50).

Iatrogenic changes to sensory and thermoregulatory nerves in the reconstructed breast skin of these cases are thought to lead to the inability to detect painful stimuli or dissipate heat, increasing the risk for burns (50). Most cases occur following solar radiation to the area but burns following thermal radiation from postoperative warming lights, heating pads, sunlamps, hairdryers, electric curlers, and hot dishes have been described (50). In such cases, obtaining a pertinent clinical history is crucial in differentiating burns from mimickers including RBS or erysipelas. Therapy for burns includes conservative treatment with dressings or surgical debridement and flap or graft repair in more severe cases (50). Antibiotics may be administered in cases with overlying infection (51).

**Keloids**

Keloids are common pathological scars that grow beyond the boundary of the original wound into surrounding healthy skin with an erythematous leading edge (52). Keloids are often with pruritic, cosmetically distressing,
and can be painful and reduce quality of life (53). Pathogenesis is thought to be related to overactivation of fibroblasts via chronic overexpression of TGF-β isoforms expressed in the normal wound healing process (52). On histopathology, fibroblasts and excessive accumulation of collagen are seen (52).

Unlike hypertrophic scars that can heal spontaneously, keloids commonly progress to form thick, firm scars (52). Therapeutic modalities include intralesional steroid or 5-fluorouracil injections, silicone gel or sheets, topical therapies including tacrolimus and imiquimod, cryotherapy, surgery, and adjunctive radiation or laser treatment (52). Importantly, there have been rare reports of cutaneous breast cancer metastases mimicking keloids on the chest wall (54). While treatment frequently yields variable results, lesions that fail to respond to therapy may be suggestive of primary or metastatic carcinoma recurrence. Additionally, keloid-like lesions presenting more than 3 months postoperatively, outside of scars, and those with an atypical appearance should alert clinicians to the possibility of malignancy and prompt a diagnostic biopsy (54).

**Infectious**

**Surgical site infection (SSI)**

SSIs can be classified as superficial wound infections involving skin or subcutaneous tissue, deep wound infections extending into the fascial and muscle layers, or periprosthetic infection, and present with redness, delayed healing, fever, pain, tenderness, warmth, or swelling.

Risk for SSI is increased with higher BMI, diabetes mellitus, smoking, or concomitant active skin disorders, advanced tumor clinical stage, and neoadjuvant radiotherapy which is known to impair wound healing (55). Breast-conserving operations are less frequently associated with SSI than radical procedures like mastectomy or mastectomy with immediate reconstruction (55). In breast cancer patients undergoing prosthesis-based breast reconstruction risk factors for developing infection include smoking, chemotherapy, and skin necrosis following prior mastectomy (56). As mentioned, PG and RBS may mimic SSI.

Superficial SSIs are treated with wound irrigation, dressing changes, and oral antibiotics, while deep SSIs require surgical debridement and aggressive intravenous antibiotic therapy (55,57). In the case of periprosthetic infection, device salvage may be attempted using a combination of systemic antibiotics combined with antibiotic lavage, capsule curettage, capsulectomy, and device exchange with or without postoperative continuous antibiotic irrigation (56).

**Herpes zoster**

Herpes zoster, or shingles, is the reactivation of latent varicella-zoster virus in the dorsal root ganglia that follows primary infection earlier in life. Up to 1 million people in the United States are affected annually (58). Herpes zoster presents as a tender, erythematous, vesicular or pustular rash in a dermatomal distribution with a painful prodrome in the affected area. Postherpetic neuralgia, a condition presenting with intense pain persisting more than 3 months after rash resolution, is a complication of up to 70% of untreated herpes zoster patients (58). Risk factors for reactivation include old age and immunosuppression with chemotherapy (58) in breast cancer patients (59).

In postsurgical breast cancer patients presenting with zosteriform rash, more insidious diagnoses of cutaneous metastasis or disseminated herpes zoster should also be considered (58,59). When rash presents with firm papules or nodules rather than vesicles or does not resolve with treatment, malignancy may be suspected and a biopsy is indicated for diagnosis (59). Disseminated herpes zoster, a generalized form of zoster necessitating hospitalization given potential for visceral involvement, affects multiple dermatomes and crosses the midline, unlike herpes zoster and is more common in immunosuppressed patients (58). In disseminated zoster, lesions may appear nodular with chronic crusting, in which case polymerase chain reaction testing on active lesion scrapings can be helpful for diagnosis (59). Of note, iatrogenic nerve displacement during breast surgery can lead to loss of the characteristic dermatomal distribution.

Treatment for herpes zoster includes 7 days of oral valacyclovir 1,000 mg 3 times daily, foscarnet or 500 mg 3 times daily, or acyclovir 800 mg 5 times daily (59). Observation is also an option in uncomplicated patients presenting 72 hours after rash onset with no progression (59). In patients with suspected disseminated zoster or with progression after 2–3 days of oral therapy should be hospitalized and treated with intravenous acyclovir (59).

**Lymphedema-associated dermatoses**

**Lymphedema**

Lymphedema is a common, progressive condition in breast cancer patients characterized by swelling, stiffness, and neuropathy of the affected limb due to excess extracellular protein-rich fluid accumulation presenting on average 2 years
after surgery, with progression up to 11 years later to a chronic phase with irreversible intradermal fibrosis with pitting edema, hyperkeratosis, and increased tissue firmness (60). Lymphedema can also involve the breast (61). Axillary surgery and radiotherapy are risk factors with similar rates of disease regardless of sentinel lymph node biopsy or more invasive axillary lymph node dissection (61,62). Differential diagnosis can include various causes of fluid overload including heart, renal, or hepatic failure infection, as well as recurrent malignancy or vascular abnormalities (62). Early intervention with manual lymphatic drainage, compression garments, and exercise can prevent chronic irreversible disease (60,62,63). Surgical techniques to improve lymphatic circulation, such as lymphaticovenous anastomosis and vascularized lymph node transfer, have recently gained popularity (60). Lymphedema lowers patient quality of life due to cosmetic disfigurement, lack of mobility, and cost associated with decompressive treatment (60). Additionally, due to impaired immune function in the affected limb, lymphedema patients are at higher risk of developing cutaneous diseases in the affected limb, discussed in further detail below (64).

**Erysipelas**

Erysipelas is an acute bacterial infection of the dermis, presenting with fever and tender erythematous, edematous plaques with sharply-demarcated margins that spread rapidly, caused most commonly by group A beta-hemolytic streptococci (65,66). There is a well-documented association of erysipelas and lymphedema in postsurgical breast cancer patients resulting in recurrent inflammatory episodes which further damage lymphatic vessels of the affected arm increasing lymphedema severity and risk for future erysipelas infections (67). Additionally, the high protein content of the excess interstitial fluid is an ideal culture medium for bacterial growth (67). Obesity exacerbates risk of infection (68).

Erysipelas is clinically diagnosed based on rash appearance (65). A portal of entry for infection is not always identifiable on exam or based on patient history (68). Of note, erysipelas findings are sometimes described with a peau d’orange appearance, which can mimic inflammatory breast cancer (66). The lesion should be biopsied to rule out malignancy if there is no resolution following therapy. Mild cases of early erysipelas can be treated on an outpatient basis with oral penicillin monotherapy, with broader antibiotic coverage if clinical findings make exclusion of acute cellulitis difficult (66). Macrolides and clindamycin can be used in penicillin-allergic individuals (66). The average duration of antibiotic therapy is 15 days, and up to 21 days in subjects with comorbidities (68). Prophylactic antibiotic therapy in patients with lymphedema is not recommended (63), however recent data suggest that liposuction can significantly reduce erysipelas incidence in postmastectomy lymphedema patients (69). Additionally, trauma, excessive heat, constrictive clothing, exaggerated exercise, and weight gain should be avoided (66).

**Cutaneous angiosarcoma (CAS)**

CAS, also known as Stewart Treves syndrome, is a rare, aggressive angiosarcoma that develops in patients with chronic lymphedema, most commonly in breast cancer patients treated with radical mastectomy. It presents at first with subtle, poorly circumscribed erythematous lesions that over time coalesce into purpuric and erythematous macules and nodules which may ulcerate or bleed on the affected extremity. Metastatic disease is frequent, particularly in local lymph nodes and lungs (70). The average time of development after radical mastectomy is 12.5 years (71). CAS is recurrent, invasive, and commonly causes death within 1–2 years (71).

CAS pathogenesis is not yet elucidated; however malignant cells are thought to derive from blood vascular or lymphatic endothelial cells (72). Histologically, CAS appearance varies but generally shows numerous irregular vascular channels splitting dermal collagen sometimes with spindle-shaped, polygonal, epithelioid and primitive round cells and increased mitotic activity (70). Immunohistochemical staining for CD34, CD31, ERG, factor VIII, type IV collagen, C-MYC gene amplification can be helpful in diagnosis (70).

There are several mimickers of CAS including the more recently described post-radiation CAS, which differs from CAS by its shorter latency of 6 years post-lumpectomy, lack of association with lymphedema, and consistent location in the radiation field. Lymphangioma circumscriptum, presenting as erythematous deep seated vesicles described as resembling frog spawn, has been reported in postmastectomy lymphedema and may mimic CAS (71). Additionally, sarcoid reaction (73) presenting on the post-mastectomy arm with red papules and nodules, or siliconomas (74) presenting as pink nodules secondary to breast implant rupture have been reported and may mimic angiosarcoma.

There are no standardized management guidelines, but wide local excision and postoperative radiation to decrease the risk of recurrence is most common (70,75). Drugs that
target VEGF signaling, as well as new cytotoxic anticancer drugs including denibulin or trabectedin show promise (75).

**Neutrophilic dermatosis on site of lymphedema**

Neutrophilic dermatosis on the site of postmastectomy lymphedema has been reported in 12 cases in women aged 39–75 years (76). It presents as multiple painful, tender, erythematous papules, which may coalesce to form irregular sharply bordered plaques, sometimes with blisters (76). Unlike the classic neutrophilic dermatosis, Sweet syndrome, systemic symptoms and neutrophilic leukocytosis are mild or absent, relapses are less common, and lesions are restricted to arm affected by lymphedema and resolve without scarring (76,77). Onset from time of breast surgery and cutaneous disease onset ranges from a few months to several years (76). Biopsy reveals a dense infiltrate primarily composed of neutrophils and localized in the dermis (76,78). Pathogenesis is thought to be related to local cytokine accumulation or increased antibody deposition due to inadequate lymphatic draining attracting neutrophils to a site of altered immunocompetence (76).

The differential diagnosis includes other entities presenting with erythematous nodules or plaques including erysipelas, folliculitis, herpes zoster, contact dermatitis, or cutaneous metastases, which can be differentiated via clinical course and biopsy findings (77,78). Treatment includes systemic antibiotics or corticosteroids, or potassium iodide, but disease may also spontaneously remit (77,78).

**Delayed breast cellulitis (DBC)**

DBC is a newly reported complication of breast conserving therapy with an incidence of up to 12% (79–81). It presents with diffuse breast erythema, edema or peau d’orange, tenderness, and slight warmth, sometimes with improvement after laying, occurring 3 months after surgery. Unlike acute cellulitis, DBC has a lower incidence of systemic symptoms, is more insidious, and recurs in up to 22% of patients (79,81). Arm lymphedema and removal of ≥5 axillary lymph nodes, as well as seroma or hematoma aspiration, obesity, and higher stage cancer are associated with higher risk of DBC (81-83).

It is not yet clear whether DBC is primarily of infectious or inflammatory etiology. DBC may be caused by bacterial infection in the setting of impaired lymphatic drainage (84,85), particularly given reports associating DBC with known sources of infection (86). Others suggest a cyclic inflammatory reaction to protein exudate in patients with lymphedema causes DBC as indicated by the rare isolation of pathogens and lack of constitutional symptoms in most cases (81,87).

The differential diagnosis importantly includes inflammatory breast cancer, which also presents with an edematous and erythematous breast but can be definitively diagnosed via biopsy. Other mimickers of DBC presenting with an erythematous breast include reticular telangiectatic erythema due to non-absorbable suture (88), as well as foreign body reaction to due inadvertent reversed placement of ADM that resolved with ADM removal (89). Finally, squamous cell carcinoma of the implant capsule following reconstruction has been reported and can mimic the clinical course of DBC (90).

Optimal treatment is debated, as some authors find complete resolution with 10–14 days of empiric antibiotic therapy (91), while other have found that most cases resolved without antibiotic treatment (79). As noted previously, patients should be educated regarding lymphedema precautions so that chronic fibrotic skin changes and DBC risk may be minimized (82). If the condition persists after 4 months of antibiotic therapy, a biopsy should be performed to rule out malignancy (87); however mean time to resolution of symptoms has been described to be 7.5 months (79).

**Conclusions**

Surgical resection of malignancy and breast reconstruction in breast cancer patients can result in many dermatologic sequelae affecting the breast and ipsilateral limb. It is crucial that healthcare practitioners are aware of relevant cutaneous changes to appropriately diagnose or rule out infection or malignancy and obtain timely treatment to improve patient outcomes and quality of life. Our review supports the need for further investigations to define the etiology and optimal treatment of RBS and DBC, as well as effective angiosarcoma treatment.

**Acknowledgments**

Funding: None.

**Footnote**

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://abs.amegroups.com/article/view/10.21037/abs-22-39

Peer Review File: Available at https://abs.amegroups.com/
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://abs.amegroups.com/article/view/10.21037/abs-22-39/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


46. Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez

47. Goossens A, Verhamme B. Contact allergy to permanent colorants used for tattooing a nipple after breast reconstruction. Contact Dermatitis 2002;47:250.


doi: 10.21037/abs-22-39